Skip to content

Registration study of cases of wangbi tablets for the treatment of knee osteoarthritis

Registration study of cases of wangbi tablets for the treatment of knee osteoarthritis

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100053812
Enrollment
Unknown
Registered
2021-11-29
Start date
2018-12-02
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee osteoarthritis

Interventions

case series:None

Sponsors

The Third Hospital of Beijing University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. In line with the diagnostic criteria for osteoarthritis formulated by the Orthopaedic Branch of the Chinese Medical Association in 2018 ''Guidelines for the Diagnosis and Treatment of Osteoarthritis'': (1) Repeated knee pain in the past 1 month; (2) X-ray films (standing or weight-bearing) showed narrowing of the joint space, subchondral bone sclerosis and/or cystic degeneration, and the formation of osteophytes at the joint edge; (3) Aged >= 50 years; (4) Morning stiffness time <= 30 min; (5) Bone fricative (sense) during activity; Note: Satisfying diagnostic criteria 1+ (any 2 of 2, 3, 4, and 5) can diagnose knee osteoarthritis. 2. Aged 30 to 70 years (including 30 and 70 years old).

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
effectiveness;overall quality of life;safety;patient satisfaction;

Countries

China

Contacts

Public ContactLi Helin

Beijing Yaohainingkang Pharmaceutical Technology Co., Ltd.

lihelin@zyyjypj.cn+86 13693297970

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026